AU2017277532B2 - Compounds for delivering glutathione to a target and methods of making and using the same - Google Patents

Compounds for delivering glutathione to a target and methods of making and using the same Download PDF

Info

Publication number
AU2017277532B2
AU2017277532B2 AU2017277532A AU2017277532A AU2017277532B2 AU 2017277532 B2 AU2017277532 B2 AU 2017277532B2 AU 2017277532 A AU2017277532 A AU 2017277532A AU 2017277532 A AU2017277532 A AU 2017277532A AU 2017277532 B2 AU2017277532 B2 AU 2017277532B2
Authority
AU
Australia
Prior art keywords
aryl
heteroaryl
aliphatic
heteroaliphatic
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017277532A
Other languages
English (en)
Other versions
AU2017277532A1 (en
Inventor
Joseph S. Beckman
Pamela R. Beilby
Tory M. Hagen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon State University
Original Assignee
Oregon State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon State University filed Critical Oregon State University
Publication of AU2017277532A1 publication Critical patent/AU2017277532A1/en
Application granted granted Critical
Publication of AU2017277532B2 publication Critical patent/AU2017277532B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017277532A 2016-06-09 2017-06-07 Compounds for delivering glutathione to a target and methods of making and using the same Active AU2017277532B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662348030P 2016-06-09 2016-06-09
US62/348,030 2016-06-09
PCT/US2017/036393 WO2017214297A1 (en) 2016-06-09 2017-06-07 Compounds for delivering glutathione to a target and methods of making and using the same

Publications (2)

Publication Number Publication Date
AU2017277532A1 AU2017277532A1 (en) 2018-12-20
AU2017277532B2 true AU2017277532B2 (en) 2022-09-15

Family

ID=60578926

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017277532A Active AU2017277532B2 (en) 2016-06-09 2017-06-07 Compounds for delivering glutathione to a target and methods of making and using the same

Country Status (7)

Country Link
US (2) US20190106456A1 (OSRAM)
EP (1) EP3468563B1 (OSRAM)
JP (3) JP7482495B2 (OSRAM)
AU (1) AU2017277532B2 (OSRAM)
CA (1) CA3025665A1 (OSRAM)
IL (1) IL263469B (OSRAM)
WO (1) WO2017214297A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113456825B (zh) * 2021-06-17 2023-07-11 温州医科大学 一种线粒体靶向的谷胱甘肽衍生物纳米制剂及应用
CN113480595B (zh) * 2021-06-17 2023-07-11 温州医科大学 一种线粒体靶向谷胱甘肽衍生物、制备方法及应用
WO2024172390A1 (ko) * 2023-02-13 2024-08-22 가톨릭대학교 산학협력단 신규한 미토콘드리아 표적화 화합물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069208A1 (en) * 1997-11-25 2003-04-10 University Of Otago Mitochondrially targeted antioxidants
US20070142267A1 (en) * 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US6747009B2 (en) * 2002-09-19 2004-06-08 Universiteit Leiden Peptidomimetic glutathione analogs
AU2004293477A1 (en) * 2003-11-25 2005-06-09 University Of Rochester Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
EP2398500B1 (en) * 2009-02-20 2019-03-13 2-BBB Medicines B.V. Glutathione-based drug delivery system
WO2013177293A1 (en) 2012-05-22 2013-11-28 Biogen Idec Ma Inc. Trapping reagents for reactive metabolites screening
US20160129070A1 (en) 2014-11-10 2016-05-12 South Dakota Board Of Regents Glutathione Disulfide Compositions and Related Methods for the Treatment of Cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHEU, S. et al., 'Targeting antioxidants to mitochondria: a new therapeutic direction', Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2016, vol. 1762(2), pages 256-265 *

Also Published As

Publication number Publication date
EP3468563B1 (en) 2023-09-13
AU2017277532A1 (en) 2018-12-20
EP3468563A1 (en) 2019-04-17
CA3025665A1 (en) 2017-12-14
IL263469A (en) 2019-01-31
JP2019518029A (ja) 2019-06-27
WO2017214297A1 (en) 2017-12-14
JP2022137094A (ja) 2022-09-21
US20250282817A1 (en) 2025-09-11
JP7482495B2 (ja) 2024-05-14
IL263469B (en) 2022-08-01
EP3468563A4 (en) 2020-07-29
JP2024150504A (ja) 2024-10-23
US20190106456A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
US20250282817A1 (en) Compounds for delivering glutathione to a target and methods of making and using the same
WO2009052116A1 (en) Methods for treating a variety of diseases and conditions, and compounds useful therefor
EP3873466B1 (en) Phosphate compounds for detecting neurological disorders
CN105764909B (zh) 用于治疗泛酸激酶相关神经变性(pkan)的稳定泛酰巯基乙胺衍生物及用于合成这样的化合物的方法
EP4126836A1 (en) Compositions and methods for the prevention and/or treatment of mitochondrial disease, including friedreich's ataxia
JP2025164962A (ja) ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体
AU2004293477A1 (en) Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
CN111417620A (zh) 肌酸前药、其组合物以及使用方法
WO2021055639A1 (en) Methods of detecting neurological disorders via binding to phosphorylated tau protein
WO2023165459A1 (en) Compounds as sars-cov-2 inhibitors
US6759406B1 (en) Quaternary ammonium compounds
JP2020532538A (ja) 治療用金属錯体およびリガンドならびにその作成および使用の方法
US20090318454A1 (en) Novel antioxidants and methods of treatment
WO2022125613A1 (en) Phosphonates as inhibitors of enpp1 and cdnp
US20210380558A1 (en) Beta-catenin and b-cell lymphoma 9 (bcl9) inhibitors
US20060160748A1 (en) Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
US10137097B2 (en) Non-peptidic GAPDH aggregation inhibitor
US20250289848A1 (en) Peptidomimetic inhibitors of b-catenin/tcf protein-protein interaction
CN114127078B (zh) 杂化合物及其使用方法
US20240254098A1 (en) Thioester prodrugs for the treatment of renal anomalies
US20200171016A1 (en) Multi-targeting agents for alzheimer's disease therapy
HU229084B1 (en) Quaternary bis-ammonium salt precursors and their uses as prodrugs having an antiparasitic activity
US20110257107A1 (en) Compounds for Delivering Amino Acids or Peptides with Antioxidant Activity into Mitochondria

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)